Table 4.
Summary of adverse events reported in the study.
| Placebo (N = 25) | AHCC (N = 25) | |
|---|---|---|
| Nausea | 2 (8%) | 1 (4%) |
| Bloating | 1 (4%) | 1(4%) |
| Heartburn | 0 | 1 (4%) |
| fatigue | 0 | 1 (4%) |
All patients enrolled were included in safety analysis for adverse events. Overall, no study patients reported greater than grade 1 toxicity on either placebo or the AHCC supplement arm. AHCC was well tolerated compared to placebo.